Welcome to the Newsroom
22 December 2016
Prima BioMed Announces Data from IMP321 AIPAC Clinical Trial in Breast Cancer
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) today announced interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer (Active Immunotherapy PAClitaxel). The initial data confirms previous trial results showing IMP321 is safe and well tolerated.
Article as pdf